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“Consisting of separate parts that, when combined, form a complete whole”
Definition of modular provided by the Cambridge Dictionary
In this thesis, we are exploring the different modular approaches that can be found within the 
interdisciplinary field of positron emission tomography (PET) imaging. These approaches 
involve modularity within the design of imaging agents and PET tracers, chemical reactions for 
radiosyntheses and automation processes and how we can utilize modularity to increase the 
binding affinity of our PET-tracers. Herein, we are following the definition provided by the 
Cambridge Dictionary, namely that modularity describes a system built of different parts, 
building blocks or functionalities. In this chapter, we are introducing the different areas of 
modularity that are covered within this thesis, which includes modularity in medical imaging, 
radiotracers and chemistry.  
1.2 Medical imaging 
The rapid development of clinical diagnostics employing non-invasive medical imaging 
provides a broad spectrum of different techniques, which enable the specific visualization of 
inner body structures and processes. For this purpose, there are modalities specifically designed 
for imaging anatomy, such as X-ray or computed tomography (CT) [1] used for the visualization 
of dense tissue structures, and magnetic resonance imaging (MRI) [2] or ultrasound [1] for soft 
tissue. Physiological and biochemical processes can be visualized by single-photon emission 
computed tomography (SPECT) or positron emission tomography (PET) [1,3]. Recently, optical 
imaging devices are increasingly used in clinics, for instance near-infrared fluorescence (NIF) 
to study the blood oxygen saturation for vascularization and perfusion [4] or fluorescence-guided 
surgery to visualize the diseased tissue intraoperatively [5]. Depending on the medical imaging 
technique and the biomarker that is aimed to be visualized, contrast media or imaging agents 
are required to enhance the contrast of the image [6]. Imaging agents are composed of a ligand 
that binds to a specific target or participate in certain processes within the body and an imaging 
tag, such as fluorophores or radionuclides [7]. 
Modularity in medical imaging can be found in combination of medical imaging devices, in 
which PET with CT or MRI are combined towards hybrid systems and the obtained images 
provide the combined anatomical and physiological information [1,8,9]. But we can also find 
modularity in ‘theranostics’, in which the diagnosis, in form of medical imaging, is combined 
with therapy, which are often radiotherapeutic [10,11] and photodynamic therapeutic approaches 
[12,13]. In the following, we are focusing on PET imaging and their radioactive imaging agents, 
the so-called radiotracers.  
1.2.1 Positron Emission Tomography 
PET is a non-invasive, molecular imaging technique to visualize physiological processes within 
the body and is based on positron-emitting radionuclides. The principle of PET imaging is 
shown in Figure 1, using [18F]fluoro-deoxy-D-glucose as an example, which is a radioactive 
variant of D-glucose where the 2-hydroxyl-group is replaced by radioactive fluorine-18. 
[18F]Fluoro-deoxy-D-glucose is taken up via the glucose metabolism, but cannot be processed 
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further than the phosphorylation during glycolysis and is consequently trapped in the cell and 
is used to visualize the glucose-consumption of cells, which can be an indication for cancerous 
tissue [1]. After injection of the radiotracer, the radionuclide is undergoing radioactive decay 
through +- decay, which is the main decay pathway for such radioisotopes as carbon-11 (t1/2 = 
20.4 min, >99.9 % +) and fluorine-18 (t1/2 = 109.7 min, 96.9 % 
+) [14,15] providing a high 
positron yield which is desirable for imaging purposes. During the +-decay, the radionuclide 
releases a neutrino and a positron (+), a positively charged electron [16], see Figure 1. When 
the positron collides with an electron, it annihilates. During the annihilation, two -photons of 
511 keV energy are released in opposite directions, with an angle of 180o, given the energy of 
this collision was equal or higher than 1022 keV [16,17].  
Figure 1. The principle of positron emission tomography (PET) imaging. PET imaging requires the application
of radiotracers, which need to be synthesized shortly prior to the scan. The radiosynthesis is most commonly a 1- 
to 2-step reaction and depending on the radionuclide, involves the replacement of a leaving-group or chelation of 
a radiometal [19]. Here, we illustrated the synthesis of [18F]fluoro-deoxy-D-glucose ([18F]FDG) where the 
radiolabeling is based in the replacement of a leaving group by the radionuclide complexed with a cryptand 
[18F]KF/K222 [20]. Once the radiotracer is injected, it is accumulating in the targeted tissue. During the decay, a 
positron is released that can annihilate with an electron, which produced two -photons in opposite directions [17]. 
These -photons induce the activation of the detectors, where the detection of both -photons originated by the 
same annihilation is called coincidence [17]. Based on this information, the final image can be reconstructed.  
Every radionuclide has a specific positron energy, see Table 1 for a brief overview, which can 
be released as kinetic energy. The kinetic energy release enables the positron to travel 
throughout the tissue. The travelled distance is known as the range of a positron [1]. Therefore, 
positron energy has a direct influence on the resolution of the PET image, as it mainly 

























Table 1. Overview of the most prominent PET radionuclides, their half-lives, positron yields and positron 
energies which determine their travel distance, here provided as mean range.  
The -photons produced during the annihilation are traced with detectors, built of scintillators 
and photomultipliers, by capturing their coincidence [17]. Their output is a sinogram, which can 
be recalculated using algorithms to the final PET image [17]. 
1.2.2 Radiotracer 
PET imaging requires the application of radionuclide containing imaging agents. These 
imaging agents are either called radiotracers or radiopharmaceuticals [25,26], and both terms are 
still being used interchangeably [25]. For clarification, this thesis uses the term radiotracers to 
include all radiolabeled compounds, while the term radiopharmaceuticals is used for the final 
formulated product applicable for intravenous injections in vivo that meet the high standards of
pharmaceuticals [25,27], in terms of purity and functionality and additionally molar activity and 
radiochemical purity [28]. As the presented radioactive compounds described in this thesis are 
all used in the research and development setting, we are mainly using the term radiotracer 
throughout.  
The type of radionuclide used in a radiotracer is of main importance for the spatial resolution 
of the image (vide supra), as their positron energy is a main indicator how far the positron can
travel within the tissue. However, the final image contrast is even more related to the imaging 
agent itself. Radiotracers are constructs of the chosen radionuclides and either (partly) 
metabolically active compounds such as [18F]FDG and [13N]NH3, receptor- and enzyme- 
specific targeting agents through the application of small molecules like [18F]PSMA-1007 or 
antibodies like [89Zr]trastuzumab [22,24,29]. The image contrast is strongly dependent on the 
receptor density Bmax and the binding affinity expressed as the dissociation constant Kd, as 
sufficient image contrast requires at least a Bmax Kd
-1 ratio of 4 [29] and preferably higher.  
However, in order to be able to produce the desired radiotracer, the 3 fundamental pillars of 
radiotracer accessibility should be considered: [30].  
1) Radionuclide production: The most common production of the clinically- used
radionuclides carbon-11 (via 14N(p,α)11C nuclear reaction), fluorine-18 ( via 18O(p,n)18F
nuclear reaction) and nitrogen-13 (via 16O(p,a)13N nuclear reaction) is by a cyclotron,
which is a particle accelerator and produces a high energetic proton beam [30]. The




Range Example Ref. 
Carbon-11 20.4 min 99.9 % 960 keV 1.2 mm [11C]choline, [11C]PIB [14,19,20] 
Fluorine-18 109.7 min 96.9 % 635 keV 0.6 mm [18F]FDG [14,19,20] 
Oxygen-15 2.03 min 99.9 % 1720 keV 3.0 mm [15O]H2O [14,19,21] 
Nitrogen-13 9.97 min 99.8 % 1190 keV 1.2 mm [13N]NH3 [14,19,21] 
Rubidium-82 1.3 min 81.8 % 3150 keV 7.1 mm 82Rb [14,19,21,22] 
Gallium-68 67.8 min 87.7 % 1900 keV 3.5 mm [68Ga]DOTATOC [14,19] 
Copper-64 12.7 h 17.5 % 653 keV 0.7 mm [64Cu]ATSM [14,19,23] 
Zirconium-89 78.4 h 22.7 % 902 keV 1.3 mm [89Zr]trastuzumab [14,19,24] 
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radionuclide-specific target is bombarded with the proton beam, resulting in the 
production of the desired radionuclide [30]. Another method is the application of a 
generator to produce radiometals.  
2) Methodology for radiosynthesis: It is important to have short reaction times in order to
get sufficient amounts of radiotracer. This is due to the fact that nuclear medicine mostly
uses short-living nuclides [30]. Additionally, a guideline is given to achieve molar
activities of around 30 GBq mol-1 [29].
3) Radiotracer production: The production of a radiotracer in sufficient amounts for patient
doses requires quite high amounts of starting materials. In order to prevent the
radiochemists from exposure, it is necessary to automate the production [30]. This also
ensures reproducible reaction conditions and eliminates contaminations, which can be
caused by the worker.
Within these 3 pillars, we can find modularity in the second and third pillar: Methodology of 
radiosynthesis and radiotracer production. While the methodology is based on the chemistry 
and radiochemistry, the radiotracer production aims for the implementation of a radiotracer into 
the clinical setting by automated radiotracer production [31,32]. The field of chemistry allows the 
application of diverse reactions that are suitable for the radiosynthesis, however only a few can 
actually be called modular (vide infra). As the clinical radiotracer production requires synthesis
automation, these radiosyntheses are produced in specific cassette- based radiosynthesis 
modules [33]. More modules and procedures to synthesize more radiotracers become 
continuously commercially available. This shows that these radiosynthesis modules can be 
adapted for several different radiotracer productions.  
1.3 Disease-specific targeting of radiotracer
Unlike pharmaceuticals, radiotracers do not show any pharmacological effect, due to the low 
amounts that are injected [27]. However, radiotracers need to show highly specific and selective 
binding, fast clearance of non-bound radiotracers, low protein or blood-cell binding, low non-
specific binding, lack of toxic effects and high in vivo stability [27,29]. Additionally, the
lipophilicity should match the requirements for desired target to allow, if necessary, the 
penetration of the blood-brain-barrier [27,29]. Additionally, the radiotracer should allow the study 
of pharmacokinetics and enable quantification, which is not possible for metabolized 
radiotracers [27,34]. However, these are generic applicable properties of radiotracers and need to 
be adjusted to every disease that is aimed to be visualized and quantified. In this thesis, we are 
exploring modular radiotracers in the context of prostate cancer and heart failure. In the 
following section, the health-related concerns are introduced with specific attention to the role 
of medical imaging in their diagnostics. 
1.3.1 Prostate cancer 
Statistically, every 5th case of cancer among the male European population in 2018 was prostate 
cancer (PCa) [35]. Prostate cancer has different risk factors, with age being the main factor and  
the highest incidence rate in men >65 years with a percentage of around 60 % [36]. As the 








[37]. This presents a problem for the health care systems due to the high economic burden, which 
in 2006 was estimated to be 107 – 179 million € in Europe (UK, Germany. France, Spain, 
Netherlands, Italy) for the care provided only within the first year after diagnosis [38].  
PCa ranges from an asymptomatic, low-grade cancer stage to an aggressive high-grade cancer 
with the formation of metastasis or even the development towards castration-resistant prostate 
cancer [39–41]. Nowadays, the assessment of the prostate-specific antigen (PSA) level in blood 
or a digital rectal exam are already part of the standard care, and the gold standard of PCa 
diagnosis is usually the transrectal ultrasound-guided (TRUS) biopsy [42]. However, depending 
on the positioning of the needle, a biopsy can give a false-negative result or an under- or 
overestimated stage of the disease [43]. Therefore, the European Association of Urology 
suggested in 2019 to include PET-CT scans into the standard care for biochemical recurrent 
cased of PCa after prostatectomy [44]. 
In the field of nuclear medicine, several radiotracers for PCa were evaluated [45,46]. [18F]FDG 
application in PCa is limited, since PCa is characterized as having a low glycemic activity, 
which results in low [18F]FDG uptake [41]. Other radiotracers were [11C]choline, which showed 
a strong relation to the PSA level, sodium-[18F]fluoride for the detection of bone metastases 
and [18F]fluciclovine for recurrent and extra-prostatic PCa [45]. During the last years, nuclear 
medicine focused on finding new targets for the early diagnosis of prostate cancer [47]. One 
example is the overexpressed gastrin-releasing peptide receptor (GRPR). GRPR can be targeted 
with Bombesin, which is an analog of the human gastrin-releasing peptide and is constructed 
out of 14-amino acids [45]. Radiotracer examples using Bombesin are [68GA]AMBA [45], 
[18F]PESIN [48,49] and more [50,51].  
The visualization of prostate cancer was revolutionized by the discovery of the presence and 
overexpression of the prostate specific membrane antigen (PSMA) in 1993 and 1995, 
respectively [52,53]. The indium-111-labelled monoclonal PSMA-antibody capromab pendetide, 
better known as ProstaScint, is the first Food-and Drug Administration (FDA) approved PET-
tracer for PCa used in clinics [54–56]. However, the disadvantage of ProstaScint is the long 
circulation time of the antibody, which decreases its imaging potential [57]. Therefore, research 
was performed towards finding small molecular weight molecules targeting PSMA. Several 
tracers were developed and published with very promising results, including three main binding 
motifs – thiol-based, phosphoric acid-based, and urea-based PSMA Inhibitors (Figure 2) [58].  
Figure 2. Different binding motifs for targeting the prostate specific membrane antigen [58].
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[68Ga]PSMA-HBED-CC was the first clinically used radiotracer targeting PSMA [59] and it is 
based on the urea-based glutamate-urea-lysine (Glu-urea-Lys) binding motif [60]. Despite its 
high diagnostic potential, the production capacity is limited as one production yields only a few 
patient doses [61]. Additionally, gallium-68 has a positron energy of 
1.9 MeV and a lower positron yield than fluorine-18 (635 keV), which results in a lower 
positron sensitivity as well as resolution of the final image [18,61]. This fact promoted the 
development of fluorine-18-based PSMA tracers for PCa imaging [18]. In 2016, the Kopka group 
published the first clinical data of [18F]PSMA-1007 [62]. [18F]PSMA-1007 consists of the same 
PSMA-binding motif based on Glu-urea-Lys [61,62]. Despite the fact that nowadays the field of 
nuclear medicine is well equipped with radiotracers for PCa, even at different stages, PSMA 
became a universal showcase for new imaging techniques as it provides high binding potentials 
and is also used in this study.  
1.3.2 Heart Failure 
Unlike PCa, research on heart failure (HF) is less prevalent in radiochemistry and 
radiopharmaceutical sciences. However, >37.7 million people are estimated to suffer from HF 
globally [63]. Although usually HF refers to several cardiac diseases, it is defined as the complex 
clinical syndrome related to structural and functional impairment of the ventricles [63,64]. HF can 
be specified into two main groups: 1) preserved ejection fraction, showing an ejection fraction 
of more than 50 % (HFpEF), and 2) reduced ejection fraction (HFrEF), in which the ejection 
fraction is below 40% [63]. It was shown, that HFrEF mainly occures within the male population, 
while HFpEF is mainly found in women [64,65]. Both types are related to a left ventricular 
dysfunction, which lead eventually to worsening of the disease caused by prolonged 
compensational actions of the adrenergic and neuro-hormonal system [66]. 
Patients suffering from HFrEF usually have comorbidities, in which not only the left ventricle, 
but also the right ventricle is affected, often caused by coronary artery diseases with myocardial 
infarction [64]. HFpEF is mainly developed in cases with a history of hypertension, obesity and 
diabetes mellitus [64]. Other comorbidities such as coronary artery disease and atrial fibrillation 
can also occur [64]. The difficulty in diagnosing HF is that it has non-specific symptoms [63]. 
Typical signs and symptoms, among others, are fatigue, anorexia, confusion, dyspnea and 
edemas, elevated jugular venous pressure and tachycardia, [67].  
With this clinical challenge in mind, researchers are aiming to find useful biomarkers that can 
be used for diagnosis, but also fundamental research [68]. In the last years, medical imaging 
methods, such as echocardiography, cardiac magnetic resonance or computed tomography and 
fusion imaging including PET/CT, evolved to frequently used imaging modalities for the 
evaluation of the left ventricle function for monitoring HF [69]. PET/CT scan using [15O]H2O is 
commonly used to analyze the myocardial perfusion, combined with the visualization of 
coronary artery stenosis [69]. Quantification of the obtained PET data allows the assessment of 
the blood flow and reserved flow [70]. [18F]FDG proved to be useful in the viability imaging of 
the myocardium, which is an important factor in the recovery phase from HF [70]. But [18F]FDG 
also evolved to be a useful imaging agent for the diagnosis of right ventricle HF and pulmonary 








- Reaction must be wide in scope
- High yielding
- Harmless by-products, that can easily be removed
- Stereospecific, however not enantiomer specific
- Ideally commercially available starting materials
- Reaction should proceed neat or in aqueous solutions
- With simple product purification
A common feature of all click reactions is that they have a high thermodynamic driving force 
of >20 kcal/mol, which results in fast reaction times [86,87]. Due to these characteristics, click 
reactions are very suitable for radiotracer synthesis [88] that requires short reaction times. The 
prototypical click reaction is the cycloaddition of azides with alkynes [86], strongly based on the 
seminal contribution of Prof. Rolf Huisgen, who passed away earlier this year shortly before 
It was found that meta-[123I]iodobenzylguanidine ([123I]MIBG) is a useful imaging agent for 
the patient risk stratification, as it visualized the adrenergic neuron function [73] to identify the 
presynaptic norepinephrine homeostasis imbalance [74]. This is an early stage biomarker, as the 
neuro-hormonal system is responsible for the compensational effect caused by the functional 
loss related to HF. Therefore, the neuro-hormonal system activates the 1- and 2- as well as 
α1-adrenergic receptors [75]. However, this leads in time to myocardial toxicity, related to 
arrhythmias, tachycardia and decreased ejection fraction [75]. The standard treatment is blocking 
the endogenous and neuro-hormonal axis by using -blockers that specifically bind to the -
adrenergic receptors (ARs) [75]. This is due to the fact that ARs are the main adrenergic 
receptors present on the myocardium, with 80 % of them being 1ARs [76,77]. However, the 
ARs show desensitization due to overstimulation and a receptor density loss during the 
progress of HF [78,79]. Therefore, cardiologists together with the PET imaging community 
became interested in targeting and quantifying the receptor density of cardiac selective 1ARs 
[80–82]. With this interesting finding of a reduced 1AR density on the myocardium, we are 
aiming in this thesis to improve the binding affinity of ARs ligands for future PET imaging 
and quantification applicable in the early stages of HF.  
1.4 Modularity in Radiotracer Methodology 
The second pillar of radiotracer accessibility involved the methodology of radiotracer synthesis. 
Modularity in chemical reactions can be widely found [83] in the form of (molecular) building 
blocks and peptides that are coupled together [84,85]. However, radiosynthesis also requires being 
fast while they give high yields and are easy to purify, ideally stereospecific, in order to provide 
a reliable and active radiotracer. Considering these characteristics of a modular and fast 
reaction, high efficiency and easy to purify, click reactions are among the first reactions that 
come to mind as they fulfill these requirements for a high degree (vide infra).  
1.4.1 Click chemistry 
Click chemistry, introduced in 2001 by Kolb, Finn and Sharpless, describes the regiospecific 
connection of building blocks to enable the synthesis of pure molecular entities [86]. However, 
reactions are only privileged to bear this name when they fulfill several criteria [86]:  
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his 100th birthday [89]. His groundbreaking discoveries, however, still live on and have inspired 
seminal developments. One of them is the introduction of the principle of [3+2]-cycloadditions 
using 1,3-dipolar compounds forming a 1,2,3-triazole [90,91]. Hence, this reaction is also known 
as Huisgen azide-alkyne cycloaddition [86]. The reaction is based on the 1,3-dipolar azide,
which forms a 4π-system that reacts with dipolarophiles alkyne that can provide 2π electrons 
[92], as simplified in Figure 3. 
Figure 3. General [3+2]-cycloaddition reaction of 1,3-dipolar compounds with dipolarophiles to form a five-
membered cycloadduct.
In 2002, the copper-catalyzed variant of the Huisgen [3+2]-cycloaddition, the copper-
catalyzed azide-alkyne Cycloaddition (CuAAC) was reported individually by the research
teams of Meldal and Sharpless [90,93], in which copper(I) (CuI) increases the reaction speed and 
produced exclusive the 1,4-disubstituted 1,2,3-triazole [90,93]. 
It was Prof. Carolyn Bertozzi, who introduced the term ‘bioorthogonal chemistry’ in 2003 [94,95], 
which include those chemical reactions that can be performed under physiological conditions 
on biomolecules, biological processes and cells which even enables its application in vivo [95].
Herein, the azide-functionality plays a certain role, as it is highly bioorthogonal and very 
selective [94] and hence can be found in various bioothogonal reactions. The cornerstone of 
‘bioorthogonal chemistry’ was laid with the introduction of the Staudinger-Bertozzi ligation
in 2000 [96]. The Staudinger-Bertozzi ligation, which is a further development of the Staudinger
reaction, is used for the selective formation of a carboxy-amide bond through ligation of azides 
and phosphines. Herein, the azide interacts with the phosphine, to form first a phosphazide 
intermediate which undergoes intramolecular rearrangement resulting in nitrogen loss and 
obtaining an azaylide or iminophosphorane. Further rearrangement and phosphorane hydrolysis 
lead to the final selective carboxy-amide linked product [97,98]. The generic Staudinger-Bertozzi 
ligation is shown in Figure 4.  
Figure 4. Staudinger-Bertozzi ligation. 
The introduction of bioorthogonal chemistry resulted in a further development of CuAAC 
within the field of medicinal chemistry. Although it consists of two highly bioorthogonal 
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[95] – hence CuAAC is only an orthogonal reaction. Therefore, several approaches were made
to develop a bioorthogonal variant of this reaction. It was again Prof. Bertozzi who published
in 2004 the principle of Strain-promoted azide-alkyne cycloaddition (SPAAC) [99]. In
SPAAC, strained cyclooctynes are used as the alkyne-components. In the presence of an azide,
the cyclooctyne will form a triazole ring, which is promoted by a decreased activation energy
of the cycloaddition due to the ring strain release and the ring-formation proceeds without the
need for a transition metal catalyst [15,99,100]. However, this reaction has slower kinetics than
CuAAC’s [101,102].
Figure 5. Strain-promoted azide-alkyne cycloaddition.
In the following years, different click reactions were introduced into the field of 
radiopharmaceutical sciences [15,103]. Among them, the Diels-Alder [4+2]-cycloaddition which
describes the reaction of a diene with a dienophile to form a six-membered cycloadduct [104], 
see Figure 6. Similar as the [3+2]-cycloaddition, it consists of a 4π system and 2π-electrons.  
Figure 6. Diels alder reaction of butadiene and a dienophile forms a six-membered [4+2]-cycloaddition.
The fastest known click reaction by the current state of scientific knowledge is the inverse 
electron-demand Diels-Alder (IEDDA), which is also known as the [4+2]-cycloaddition of
1,2,4,5-tetrazines with an electron-rich dienophile, which can be an alkene or an alkyne.[102,105] 
This step forms a strained bicyclic intermediate, which undergoes retro-Diels-Alder reaction 
[106,107]. Oxidation of the isomers of 4,5-dihydropyridazine yields the final product of 
pyridazine, as shown in Figure 7.  
Figure 7. Inverse electron-demand Diels alder reaction of 1,2,4,5-tetrazines with an electron-rich diene.
Throughout this thesis, we are using CuAAC, as it is a well-studied, reliable and fast reaction. 
After showcasing that we can produce modular medical imaging platforms, this area can be 
expanded by using one of the mentioned click reactions above instead. Since we are using the 
CuAAC, we are describing its mechanism in the following.  
1.4.2 The Mechanism of CuAAC 
When the CuAAC was reported for the first time, Sharpless’ group proposed a mechanism, in 
which the catalytic effect is described as being based on the ligation effect of CuI with the 
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alkyne, forming an acetylide. However, the mechanism of CuAAC is still not completely 
understood [90,108,109]. The general approach is to use CuII-complexes, such as copper sulphate 
(CuIISO4 pentahydrate), that are reduced by reducing agents like sodium ascorbate 
[87]. 
However, to maintain in the reduced state CuI needs the support of a ligand for stabilization. 
Typical ligands are tris[(1-benzyl-1H-1,2,3-triazole-4-yl)methyl]amine (TBTA), sulphonated 
bathophenanthroline (SBP) and phosphoramidites, such as MonoPhos [101,109–111]. This CuI-
complex forms a π-complex with the alkyne as shown in Figure 8, which lowers the pKa of the 
alkyne, enabling the formation of a CuI-acetylide 2 [87]. The CuI-acetylide coordinates with
azide 3, followed by a nucleophilic attack of 4 [87,112], which forms eventually the CuI-triazole
5 [113]. Reaction with an electrophile or protonation of the CuI-ligand complex, decouples 
copper from 5 to form the triazole 6 [113]. The main challenge in discovering the CuAAC
mechanism and its various mechanisms found in nature is the identifications of the 
intermediates [109]. Additionally, these intermediate stages are strongly related to the CuI 
interaction with their stabilizing ligands, as monodentate and polydentate ligands showed 
different interaction [87].  
Figure 8. The CuAAC mechanism proposed by Fokin in 2013. [112]. 
However, based on the nice characteristics of the click reaction of high yielding reactions, no 
or easy-removable side products are formed and combined with the reaction speed and 
selectivity provided by CuAAC, it provides a very suitable and modular reaction, which enables 
the fast screening of different compounds, as long as they are composed out of azides and 
alkynes. In the field of medical imaging, this enables a modular synthesis approach to combine 
any imaging tag with any binding ligand without reacting with the binding site of ligand or 
facing synthetic problems in how to couple the imaging tag with ligand or protection-











































1.5 Outline of the thesis 
Medical imaging is a quickly evolving field and the interest in multifunctional imaging agents 
increase due to the fields of theranostics and hybrid imaging. Therefore, the ideal imaging agent 
is based on a modular platform that can easily be labeled with the required imaging tag 
dependent on the aimed imaging modality that is used. The aim of this thesis is to show the 
different approaches in which modular platforms can be applied in the field of PET imaging.  
Therefore, we are introducing a stepwise design approach for the design of multivalent 
molecular imaging agents in chapter 2, which introduces the requirements for the synthesis of
multivalent molecular imaging agents. Multivalency is a concept to increase the binding affinity 
– the most prominent example in our everyday life is Velcro, which is inspired by the burrs of
the burdock plant. However, multivalent imaging agents experience several challenges related
to their increased size, e.g. increased protein binding, prolonged circulation time and solubility
issues. Therefore, we summarize in this chapter several aspects of the modular
conceptualization of multivalent imaging agent that should be taken into consideration during
the design phase.
In chapter 3, we introduce a new modular platform for targeting the prostate-specific
membrane antigen (PSMA) for the PET imaging of prostate cancer. This modular platform is 
based on the copper(I)-catalyzed azide-alkyne [3+2]-cycloaddition, which is the most often 
applied click reaction variant. Here, we present the design, radiolabeling, in vitro binding
affinity and in vivo studies of the our radiotracer [18F]PSMA-MIC01 – named after our host
institute the Molecular Imaging Center – based on the novel alkyne-functionalized modular
platform, targeting PSMA.  
The radiolabeling of [18F]PSMA-MIC01 was automated using the prototype FlowSafe 
radiosynthesis module, which is a new microfluidics-based radiosynthesis module that 
combines continuous-flow with in-batch reaction technology. This prototype is introduced in 
chapter 4 and demonstrates a way of modularity in PET tracer development, to modularly
adjust the reaction conditions by changing between continuous-flow or in-batch reaction, as it 
can be easily adjusted to the requirements for different radiosyntheses. Herein, the improvement 
of the setup and the automation of the different radiotracers [18F]PSMA-MIC01, [18F]PSMA-
MIC02 (to be introduced in chapter 5), [18F]fluoro-pyridine, [18F]SFB and [18F]PSMA-1007 are 
shown, which can be achieved by only minor changes of the different modules.  
After introducing the [18F]PSMA-MIC01 for targeting PSMA in chapter 3, and its automation 
in chapter 4, we expand the concept of modularity for radiotracer development by attempts to 
increase the binding affinity of radiotracers. To this end, we aimed in chapter 5 to increase the
binding affinity by targeting the remote arene-binding site of PSMA using our alkyne-
functionalized PSMA scaffold, described in chapter 3, and we include an azide-functionalized 
modular platform and introduce an aromatic ring to our synthons, which should improve the 
binding affinity. We synthesized the PSMA-targeting ligands F-PSMA-MIC02 – F-PSMA-
MIC04 by copper(I)-catalyzed azide-alkyne [3+2]-cycloaddition. Their binding is analyzed by 
performing molecular docking and dynamic studies followed by in vitro binding affinity
studies. The radiolabeling of the ligand with the highest binding affinity is also presented. 
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In chapter 6, we explore the effect of multivalency on the binding affinity of -adrenergic
receptors, which are used as a biomarker for heart failure. After exploring the binding site of -
adrenergic receptors, a propranolol-derivative was designed and synthesized. The propranolol-
derivative was designed to have an azide-functionality for the easy multimerization by the 
copper(I)-catalyzed azide-alkyne [3+2]-cycloaddition again. In detail, the propranolol-
derivative was coupled to triethynylbenzene in order to synthesize a trimer. A consensus 
molecular docking study was performed to understand the binding of the mono- and the trimer 
within the binding pocket of -adrenergic receptors.  
The obtained results are discussed in chapter 7 and include the future perspectives, and this
thesis is summarized in chapter 8.
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